Novavax outlines $1.04B–$1.06B 2025 revenue framework and targets non-GAAP profitability as early as 2028 amid partnership-driven transition
View original at seekingalpha.comNovavax outlines $1.04B–$1.06B 2025 revenue framework and targets non-GAAP profitability as early as 2028 amid partnership-driven transition Earnings Call Insights: Novavax (NVAX) Q3 2025 MANAGEMENT VIEW * John Jacobs, President, CEO & Director, stated that Novavax has made significant progress in Q3 by strengthening e…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The BARDA grant supports Sanofi's pandemic flu vaccine candidate using Novavax's Matrix-M adjuvant
80% confidenceOver the past 8 quarters, Novavax achieved approximately $1.1 billion in nondilutive cash flow, including $800 million from partnerships
80% confidenceThe COVID market in the U.S. is down about 20% compared to last year due to policy changes and label alignment
80% confidenceOn non-GAAP basis, net of partner reimbursement, full year 2025 R&D and SG&A expected to be approximately $450 million at midpoint
80% confidence2025 priorities include optimizing Sanofi partnership, enhancing existing partnerships, leveraging technology platform for additional partnerships, and advancing technology platform and early-stage pipeline
80% confidenceFor 2026, Novavax previews adjusted total revenue expectations between $185 million and $205 million, driven in part by $75 million milestone from manufacturing technology transfer to Sanofi
80% confidenceThe non-GAAP profitability target has shifted to 2028 due to updated timelines for Sanofi's combination programs
80% confidenceMaryland campus consolidation brought in $60 million in near-term cash and anticipated long-term savings of approximately $230 million
80% confidenceNovavax intends to take a conservative position as they communicate with investors
80% confidenceThe $25 million revenue increase is driven by $7.5M increase to adjusted supply sales, $12.5M increase to Sanofi cost reimbursement, and $5M increase to other partner revenue
80% confidenceNovavax reaffirms full year 2025 combined R&D and SG&A expenses of $520 million at midpoint, narrowing range to $505M-$535M
80% confidenceNovavax reaffirms multiyear targets for 2026 and 2027 combined R&D and SG&A expenses, net of partner reimbursements, of $350 million and $250 million respectively
80% confidenceQ3 2025 combined R&D and SG&A costs were reduced by 18% compared to same period last year
80% confidenceNovavax reduced almost $1 billion in operating expenses between 2022 and 2024
80% confidenceNovavax brought in $60 million in near-term cash from consolidating Maryland sites
80% confidenceNovavax reported total revenue of $70 million in Q3 2025
80% confidenceThe $75 million 2026 milestone is tied to manufacturing tech transfer completion with Sanofi
80% confidenceNovavax uses rigorous comparator testing in preclinical programs
80% confidenceMatrix-M partner evaluations are ongoing experiments that are shorter than years, not years and years down the road
80% confidenceNovavax recorded $126 million in noncash charges in Q3 related to site consolidation and debt refinancing
80% confidenceNovavax uses a stage-gate approach for early-stage pipeline strategy and intends to partner pipeline assets
80% confidenceNovavax removed more than $1 billion of current liabilities by year-end 2024 compared to 2022
80% confidence